Human erythropoietin improves the blood platelet phospholipid composition in chronically hemodialyzed patients.
Phospholipids play an essential role in platelet structure and function. In uremic patients an abnormal platelet phospholipid pattern is observed. We examined the influence of recombinant human erythropoietin (rhuEPO) on platelet phospholipid composition in hemodialyzed patients. Before rhuEPO therapy, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylcholine were significantly reduced as compared with a healthy control group. After rhuEPO treatment, the phosphatidylethanolamine, phosphatidylinositol, and phosphatidylcholine concentrations showed a significant increase. We conclude that rhuEPO partially normalizes the platelet phospholipid composition in uremia.
Krawczyk
W
W
Department of Internal Medicine, Regional Hospital, Chelm, Poland.
Dmoszyńska
A
A
Marczewski
K
K
Ledwozyw
A
A
D000328:Adult; D001792:Blood Platelets / Q000378:metabolism*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D010713:Phosphatidylcholines / Q000097:blood; D010714:Phosphatidylethanolamines / Q000097:blood; D010716:Phosphatidylinositols / Q000097:blood; D010743:Phospholipids / Q000097:blood*; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood / Q000628:therapy*
D010713:Phosphatidylcholines; D010714:Phosphatidylethanolamines; D010716:Phosphatidylinositols; D010743:Phospholipids; D011994:Recombinant Proteins; D004921:Erythropoietin